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MaOBJECTIVES This study sought to evaluate the use of the Direct Flow Medical (DFM) transcatheter heart valve (Direct
Flow Medical, Santa Rosa, California) for the treatment of noncalciﬁc pure aortic regurgitation (AR).
BACKGROUND The treatment of noncalciﬁc AR has remained a relative contraindication with transcatheter heart
valves due to challenges in anchoring devices in the absence of calcium, concerns of valve embolization, and the high risk
of signiﬁcant residual paravalvular leak.
METHODS The study population consisted of patients treated for severe noncalciﬁc pure AR with transfemoral
implantation of a DFM transcatheter heart valve at 6 European centers. The primary endpoint was the composite
endpoint of device success and the secondary endpoint was the composite early safety endpoint (according to the
VARC-2 criteria).
RESULTS Eleven high-risk (STS score 8.84  8.9, Logistic EuroSCORE 19.9  7.1) patients (mean age 74.7  12.9 years)
were included. Device success was achieved in all patients. In 1 patient, the initial valve prosthesis was retrieved after
pull-through, and a second valve was successfully deployed. The early safety endpoint was reached in 91% of the pa-
tients, with 1 patient requiring surgical aortic valve replacement secondary to downward dislocation of the prosthesis
that was successfully managed with surgical aortic valve replacement. DFM implantation resulted in excellent hemo-
dynamics with none or trivial paravalvular regurgitation in 9 patients and a transprosthetic gradient of 7.7  5.1 mm Hg
at 30-day follow up. All patients derived symptomatic beneﬁt following the procedure, with 72% in New York Heart
Association functional class I or II.
CONCLUSIONS This study reports the feasibility of treating severe noncalciﬁc AR with the Direct Flow prosthesis via
the transfemoral route. (J Am Coll Cardiol Intv 2015;8:1842–9) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
CT = computed tomography
DFM = Direct Flow Medical
TAVR = transfemoral aortic
valve replacement
VARC = Valve Academic
Research Consortium
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1843A lthough transcatheter aortic valve replace-ment (TAVR) has become the standard ofcare for extreme- and high-risk patients
with symptomatic aortic stenosis, pure AR is still
generally considered a relative contraindication for
TAVR (1–5). This is predominantly due to the fact
that most pure AR patients can undergo surgical
aortic valve replacement even in high operative risk
situations; TAVR is still considered off-label for
almost all transcatheter valves. This is due to the
fact that TAVR valves were designed to anchor on
the native annulus in the presence of valvular calciﬁ-
cation. The absence of valvular calciﬁcation and theSEE PAGE 1850presence of large annular anatomy have made the
transcatheter treatment of pure AR a challenge
mainly because of the risk of inadequate anchoring
and sealing resulting in prosthesis dislodgment and
residual paravalvular leak. Despite this, a number of
TAVR devices designed for the treatment of calciﬁc
aortic stenosis, such as the CoreValve (Medtronic,
Minneapolis, Minnesota), JenaValve (JenaValve Tech-
nology, Munich, Germany), and Acurate TA (Symetis,
Eclubens, Switzerland), have been used off-label for
treatment of pure AR, with the JenaValve having
recently received CE-mark (Conformité Européenne) for
this indication (6–9). These devices, however, have a
number of limitations such as the risk of residual AR,
the lack of repositionability and retrievability, the need
for valve-in-valve implantation in up to 30% of the pa-
tients, or the requirement for transapical access (Acurate
TA, JenaValve) for implantation.
There is currently an unmet clinical need to have a
safe and efﬁcacious transfemoral TAVR device for
treatment of high surgical risk patients with non-
calciﬁc native pure AR. Thus, the purpose of the
present study was to evaluate the off-label use of the
fully repositionable and retrievable Direct Flow
Medical (DFM) transcatheter aortic valve system
(Direct Flow Medical, Santa Rosa, California) for this
indication.
METHODS
STUDY POPULATION. Baseline characteristics, pro-
cedural and follow-up data from patients who under-
went transfemoral implantation of the DFM valve for
symptomatic and severe pure AR from May 2014 to
April 2015 at 6 centers in Europe were retrospectively
analyzed. Patients with mixed aortic valve disease or
previous aortic valve replacement were excluded.
During TAVR work-up, all patients underwent
multimodality cardiovascular imaging includingtransthoracic and/or transesophageal echo-
cardiography, cardiac multislice computed
tomography (CT), and when required, inva-
sive cardiac catheterization. Multislice CT was
used for the accurate assessment of aortic
valve anatomy and calciﬁcation, subannular
calciﬁcations, aortic root size, height of coro-
nary ostia from the aortic annular plane, and
ﬁnal valve sizing. Valve sizing was based on
the perimeter-derived diameter on CT by using the
largest annular diameter in systole or diastole with at
least 3 mm of oversizing.
The indication for TAVR in every patient was thor-
oughly discussed and decided by a multidisciplinary
heart team at each individual center, which included
interventional cardiologists, cardiac surgeons, imag-
ing cardiologists, cardiovascular radiologists, and
cardiac anesthetists. The patient’s or physician’s
preference alone was not considered reason enough
for performing the procedure. All patients were
considered as being at prohibitive or high surgical risk
for surgical aortic valve replacement. Eligibility was
based on available surgical risk scores (Logistic Euro-
SCORE and STS Score) and other clinical (e.g., frailty) or
anatomic (e.g., porcelain aorta) variables not captured
by these scores. Comorbidities not captured by tradi-
tional risk score (e.g., frailty or porcelain aorta) were
deﬁned according to the Valve Academic Research
Consortium (VARC) II criteria (10).
All patients were informed about potential risks and
beneﬁts related to the off-label use of the DFM device.
All patients signed informed consent for the procedure
and for the anonymous and retrospective analysis of
their data for scientiﬁc purposes as per local practice
and ethics committee requirements at each center.
AR was deﬁned according to the European Society
of Cardiology guidelines (11). Post-procedural AR af-
ter initial implantation and at the end of the proce-
dure was assessed by aortography according to the
Sellers et al. (12) method, and by transthoracic or
transesophageal echocardiographic assessment, ac-
cording to VARC-2 criteria, at the end of the TAVR
procedure, at hospital discharge, and at 30 days of
follow-up. Echocardiographic assessment of post-
procedural AR was carried out by a cardiologist
experienced in TAVR echocardiographic evaluation.
Clinical and echocardiographic follow-up were per-
formed by clinical visits or telephone contacts ac-
cording to each center’s clinical practice. All events
were site reported.
DEVICE AND PROCEDURE DESCRIPTION. The DFM
transcatheter aortic valve system is a TAVR device
composed of a nonmetallic bovine pericardial tissue
TABLE 1 Demographic and Clinical Features
Patient #
Age
(yrs) Sex
Previous
CABG
Previous
MI
NYHA
Functional
Class
Creatinine
Clearance
(ml/min)
STS Score
(%)
Logistic
EuroSCORE
Reason
for TAVR
1 85 Female No Yes 2 25 7.9 17.8 Age
2 85 Female No No 2 30 8.2 17.8 Age
3 83 Female No No 3 45 7.5 19.5 High surgical risk
4 46 Male No Yes 4 58 3.8 27.3 Bridge to HTX
5 87 Female No No 4 45 9.6 31.0 Age
6 67 Male Yes Yes 3 50 3.8 17.5 High surgical risk
7 82 Female No No 3 91 3.7 9.1 Age
8 72 Female No No 3 80 5.4 13.7 IS
9 79 Female No Yes 3 18 8.9 15.7 Age, frailty
10 58 Male No No 4 23 9.4 30.8 Post-endocarditis
11 78 Male No Yes 4 46 3.5 18.3 Age, low EF
CABG ¼ coronary artery bypass graft; EF ¼ ejection fraction; HTX ¼ heart transplantation; IS ¼ immunosuppression; MI ¼ myocardial infarction; NYHA ¼ New York Heart
Association; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.
TABLE 2 Echocardio
Patient # Etiolog
1 Degenerativ
2 Degenerativ
3 Degenerativ
4 Radiation-in
5 Degenerativ
6 Traumatic l
LCC
7 Degenerativ
8 Degenerativ
9 Radiation-in
10 Post-endoc
11 Degenerativ
AR ¼ aortic regurgitation; C
NA ¼ not available; PAP ¼
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1844leaﬂet aortic heart valve, a delivery system, and ex-
change system that can be implanted either via a
transfemoral, subclavian, or direct aortic approach
and has been described elsewhere in detail (13,14). In
brief, the valve utilizes a formed-in-place support
structure with independently inﬂatable ventricular
(lower) and aortic (upper) rings, which encircle and
capture the native valve annulus thereby ensuring
positive anchoring of the bioprosthesis. After inser-
tion into the left ventricular cavity, the inﬂatable
rings are pressurized with saline and contrast solu-
tion, allowing for precise positioning, repositioning,
and retrieval, if needed. The bioprosthesis is posi-
tioned at the native annulus using 3 independent
positioning wires without hemodynamic compro-
mise, because the DFM is fully functional duringgraphic and MSCT Features
y of AR AR
ST Junction
(mm)
Sinus
Valsalva
(mm)
VC
(mm)
PHT
(ms)
Flow
Reversal
in Aorta (m
e Severe 27 32 4.5 462 Yes
e Severe 24 28 7 130 Yes
e Severe 25 32 6 458 Yes 4
duced Severe 27 35 NA NA Yes
e Severe 26 34 7 110 Yes
esion of Severe 31 36 NA NA Yes
e Severe 31 32 9 89 Yes
e Severe NA NA NA NA NA
duced Severe 28 32 4.5 NA Yes
arditis Severe 23 31 NA NA Yes
e Severe 42 35 NA NA Yes
T ¼ computed tomography; EDD ¼ end-diastolic diameter; EF ¼ ejection fraction; LCC ¼ lef
pulmonary artery pressure; PHT ¼ pressure half-time; SA ¼ sinus Valsalva; ST ¼ sinotubulpositioning. To decrease the risk of pull through in
most cases, the valve is pulled from the left ventric-
ular outﬂow tract to the native annulus more in a
parallel fashion, different from the previously
described “inner curve technique” applied in patients
with aortic stenosis (14). The aortic ring is then
pressurized and enables the evaluation of valve he-
modynamics, residual AR as well valve stability. If
residual AR is still present or the position is subopti-
mal, the aortic ring can be deﬂated to allow reposi-
tioning to achieve the best possible result. When an
optimal ﬁnal position is achieved and valve stability
is conﬁrmed by pulling and pushing the positioning
wires, the contrast–saline mixture is exchanged for a
polymer that solidiﬁes to provide the permanent
support structure to ﬁxate the valve in position.PAP
m Hg)
EF
(%)
EDD
(mm) MR Grade Calciﬁcation
CT Min
Diameter
(mm)
CT Max
Diameter
(mm)
40 50 54 Moderate None 22.0 24.5
35 55 55 Mild Mild 19.2 25.3
5–50 70 50 Mild None 17.1 29.2
40 20 72 Mild None 21.3 31.6
60 33 55 Moderate None 22.0 28.0
25 36 78 Moderate None 24.0 29.0
50 30 61 Severe Mild 24.8 27.3
NA 60 55 Mild None 18.4 24.8
45 45 53 Moderate Mild 24.3 24.8
30 58 58 Moderate None 17.0 30.0
49 26 55 Mild Mild 19.0 29.0
t coronary cusp; MR ¼mitral regurgitation; MSCT ¼multislice computed tomography;
ar junction; VC ¼ vena contracta.
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1845STUDY ENDPOINTS. All the study endpoints and
clinical outcomes were assigned according to the
VARC-2 criteria (10). The primary endpoint was the
composite endpoint of device success, deﬁned as:
absence of procedural mortality, successful vascular
access, delivery and deployment of the device, suc-
cessful retrieval of the delivery system, correct ﬁnal
position of the device, proper functioning of the
prosthetic heart valve (mean gradient <20 mm Hg,
peak velocity <3 m/s, absence of moderate or severe
AR), and no need for valve-in valve implantation or
surgical conversion. Secondary endpoints were the
early safety endpoints and post-procedural AR and at
30 days, respectively.
STATISTICAL ANALYSIS. Due to the observational
nature of the study, only descriptive statistics has
been performed. Categorical data are presented asFIGURE 1 Calciﬁcation in Multislice Computed Tomography
Multislice computed tomography of a patient with severe pure AR with a
aortic valve (bottom).frequency (percentages). Continuous variables are
expressed as mean  SD. Statistical analysis was
performed using SPSS software version 21.0 (SPSS,
Chicago, Illinois).
RESULTS
A total of 11 patients with pure AR underwent trans-
femoral implantation of the DFM valve. The mean age
of patients treated was 74.7  12.9 (range 46 to 87)
years, and the majority were female (63.6%). Baseline
clinical and echocardiographic characteristics are
shown for each individual patient in Tables 1 and 2. All
the patients treated were evaluated as being high risk
with a mean STS score of 8.84  8.90 and Logistic
EuroSCORE of 19.9  7.1. The main reason for TAVR
was advanced age and frailty (deﬁned by VARC IInoncalciﬁed aortic valve (top) and a patient with a very mild calciﬁed
FIGURE 2 Echocardiography Case Example
(A) Aortic regurgitation (AR) at baseline. (B) AR after Direct Flow
Medical valve placement.
TABLE 3 Procedural Features
Patient #
Perimeter-Derived
Diameter
(mm)
Direct Flow
wValve
(mm)
Intraprosthetic
Regurgitation
Paravalvular
Regurgitation Reintervention
1 CT without contrast
(GFR25), in
TEE 24
27 No No No
2 22.7 25 Mild Mild Valve retrieval,
2nd DFM valve
successfully
implanted
3 23.9 27 Trivial Trivial SAVR after
subacute valve
embolization
4 27 29 No No No
5 27.5 29 Trivial No No
6 25.8 29 No No No
7 27.2 29 No No No
8 23 25 No No No
9 25.9 27 No No No
10 24.8 27 No No No
11 24.1 29 No Trivial No
AV ¼ atrioventricular; CT ¼ computed tomography; GFR ¼ glomerular ﬁltration rate; DFM ¼ Direct Flow Medical;
SAVR ¼ surgical aortic valve replacement; TEE ¼ transesophageal echocardiography.
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1846[10]), except for the 46-year-old patient who had
radiation-induced aortic valve and coronary artery
disease, where multivessel percutaneous coronary
intervention and TAVR was performed as a bridge
to heart transplantation. All patients treated had
severe pure AR, and the majority (63%) had com-
plete absence of valvular calciﬁcation on CT, with
the remaining patients having mild calciﬁcation
(Figure 1). The mean perimeter-derived diameter was
24.3  2.8 mm.
All the TAVR procedures (Table 3) were performed
transfemorally with percutaneous access (Figures 2
and 3). Pre-dilation was not performed in any pa-
tient. A 25-mm, 27-mm, and 29-mm valve was
implanted in 2 patients (18%), 4 patients (36%), and
5 patients (45%), respectively. Device success was
100%. However, in 1 patient, the valve was pulled
through the native annulus into the ascending aorta
during positioning. In this case, the valve was suc-
cessfully retrieved and another DFM of the same size
was successfully implanted by switching from the
inner curve to the parallel technique as described in
the preceding text. Implantation of theDFMvalvewas
associated with excellent hemodynamics with none or
trivial paravalvular regurgitation in 10 of 11 patients
and a transprosthetic gradient of 7.7  5.1 mm Hg.
Only 1 patient had mild paravalvular regurgitation.
There were no cases of coronary obstruction,
intraprocedural valve embolization, or vascular com-
plications. Device and procedural success was thusachieved in all treated patients. The average proce-
dural time and contrast volume were 74.8  35.4 min
and 95.8  47.1 ml, respectively. None of the patients
experienced acute kidney injury, major or life-
threatening bleeding, or atrioventricular block dur-
ing hospitalization.
The composite early safety endpoint was reached
by 82% of the patients, with 1 patient requiring con-
version to surgical aortic valve replacement, and
1 patient died of noncardiovascular causes.
One patient (Patient #3) had a recurrence of severe
AR at 3 days after implantation and was found to have
a downward dislocation of the prosthesis. This pa-
tient was successfully converted to surgical aortic
valve replacement. This patient had a perimeter-
derived diameter of 23.9 mm, and a 27-mm DFM
was implanted with the ﬁnal position of the valve
slightly oblique to the native annular plane. Intra-
operatively, the annulus diameter turned out to be
larger, thus the downward displacement of the valve
was probably related to insufﬁcient oversizing and
the suboptimal ﬁnal position of the valve.
FIGURE 3 Case Example: Fluoroscopic Demonstration of Procedural Steps
(A) Aortography pre-procedural with aortic regurgitation (AR) grade III. (B) Release of the Direct Flow Medical valve in the left ventricle.
(C) Positioning of the lower ring towards the aortic annulus. (D) Additional inﬂation of the upper ring. (E) Aortography after polymer exchange
with no AR.
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1847The 30-day all-cause mortality was 9% caused by a
noncardiac death due to pneumonia and acute res-
piratory failure. There were no cerebrovascular
events, and 1 patient underwent cardiac resynchro-
nization therapy because of a severely depressed left
ventricular function. Valve function remained stable
with no change in post-procedural AR, that is, 8 of 9
patients had none or trivial paravalvular AR. All pa-
tients had derived symptomatic beneﬁt from the
procedure with 72% in New York Heart Association
functional class I or II.
DISCUSSION
The present study reporting a preliminary multicenter
experience conﬁrms the feasibility of transfemoral
implantation of the fully retrievable DFM for pure
AR in high-risk patients, with excellent procedural
success and with minimal residual paravalvular
regurgitation. It also highlights the challenges of
treating this subset of patients by transcatheter im-
plantation of aortic prostheses that were designed for
implantation in calciﬁc aortic valves and the impor-
tance of sufﬁcient oversizing to anchor the valve inthe noncalciﬁed aortic annulus. There are a number of
other complexities of treating pure AR that differ from
calciﬁc aortic stenosis, such as the diverse etiologies
of pure AR, associated dilation of the aortic root and
ascending aorta, larger annular size, and instability of
the TAVR valve during positioning due to the large
regurgitant volume (9). Because the population of
patients is perceived to be small, this has resulted in
limited development of a pure AR–speciﬁc device,
only the Helio docking system (Edwards Lifesciences,
Irvine, California), which was investigated for this
indication but meanwhile terminated (15).
The published clinical experience with trans-
catheter valves, as summarized in Table 4, has been
with self-expanding valves because of the ability to
signiﬁcantly oversize the TAVR prosthesis without the
risk of damage to the native annulus. The largest
experience has been the Medtronic CoreValve that has
been implanted retrogradely via the transfemoral,
subclavian, and direct aortic approaches. The pub-
lished data by Roy et al. (9) and Testa et al. (7) showed
high rates of valve-in-valve (19% and 30%) and resid-
ual AR (21% and 88%, respectively). This was probably
related to insufﬁcient oversizing, the inability to
TABLE 4 Overview of Studies Performed on Transcatheter Treatment of Pure AR
First Author
(Ref. #) Valve Access n
Successful
Implantation
of a THV Valve-in-Valve
Post-
Dilation
Conversion
to Surgery
None or
Trace
Residual AR
Moderate-Severe
Residual AR
Valve
Reintervention
During Follow-Up
Roy et al. (9) CoreValve Transfemoral,
subclavian,
direct aortic,
carotid
43 42 8 4 1 NR 9 0
Testa et al. (7) CoreValve Transfemoral,
subclavian,
direct aortic
26 26 5 3 0 NR 23 0
Wendt et al. (6) Symetis
Accurate
Transapical 8 8 0 2 0 8 0 0
Seiffert et al.
(8)
JenaValve Transapical 31 30 1 2 0 28 0 2
Present study DFM Transfemoral 11 10 0 0 0 9 0 1
AR ¼ aortic regurgitation; DFM ¼ Direct Flow Medical valve; NR ¼ not recorded; THV ¼ transcatheter heart valve.
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1848accurately position the prosthesis requiring rapid
pacing for valve stability, inability to reposition the
valve and insufﬁcient anchoring. The JenaValve ap-
pears to overcome many of these issues because of its
unique clip ﬁxation to the native leaﬂets and has
shown good results with a reduced need for valve-in-
valve (3%) and no patients with residual moderate or
severe AR. Similarly, the Symetis has shown promising
results albeit in only 8 patients. However, both of
these valves were implanted transapically, which may
be associated with increased risk of morbidity in high-
risk or inoperable patients, particularly those with
pure AR and a dilated left ventricle.
The unique design of the DFM offers some theoret-
ical advantages for treating of pure AR, namely: fully
functional during positioning improves hemodynamic
stability; repositionability to ﬁne tune the ﬁnal result
and decrease residual AR; and full retrievability if the
position is unstable or there is signiﬁcant residual AR.
Anchoring of the valve does not necessarily need
calciﬁcation but is ensured by adequate oversizing of
at least 2 mm compared with the size of the native
annulus. Furthermore, stability of the device can be
checked by a push-and-pull test using the positioning
wires before performing the polymer exchange and
permanently ﬁxing the device. Despite these advan-
tages, in the early phase of this study (patient #3), we
had 1 case of late ventricular displacement of the DFM
valve, which provided important learning points; that
is, the importance of oversizing the DFM valve at least
2 mm, optimal alignment of the rings parallel to the
valve plane, and proof of stability of the position by the
aforementioned push/pull test. Indeed, oblique posi-
tioning of the DFM does not take advantage of the
largest diameter of valve and may be associated with
prosthesis dislodgement.The technique of positioning the DFM may need to
be modiﬁed from that described and currently used
for treating calciﬁc aortic stenosis, that is, the inner
curve technique (16). During this technique, the part
of the DFM valve facing the inner curve of the
ascending aorta is pulled to the annulus and used as a
hinge point for pulling up the rest of the valve.
However, the large regurgitant jet in patients with
pure AR may result in the valve being pulled into the
ascending aorta when using the inner curve tech-
nique as was seen in 1 patient. In cases where it is
difﬁcult to pull the valve up to the annulus, rapid
pacing at 110 to 130 beats/min to decrease the regur-
gitant jet and a switch to the parallel technique may
facilitate implantation.
In 72.7% (8 of 11 patients), no residual para-
valvular leak was present after aortic valve implan-
tation. Two patients (18.2%) had a trivial paravalvular
regurgitation, only 1 patient (9.1%) had a mild aortic
paravalvular regurgitation. The possible cause of
paravalvular leak in this patient could be a lower
implant to prevent a pull through, which happened
during the ﬁrst attempt.
Aortic paravalvular leaks were seen in particular in
the early phase of the study. In the second half of the
patient cohort, mostly the parallel technique was
used, and care was taken to implant as high as
possible. Using this technique, there was only 1
patient with trivial residual paravalvular leak. Thus,
the difference in outcome may reﬂect a learning
curve because compared with patients treated for
aortic valve stenosis, the way to implant is slightly
different.
There are no data available so far on other
transfemorally implanted second-generation devices
for the treatment of pure AR. Compared to other
PERSPECTIVES
WHAT IS KNOWN? The treatment of noncalciﬁc AR has
remained a relative contraindication with transcatheter heart
valves.
WHAT IS NEW? This study reports the feasibility of treating
severe noncalciﬁc AR with the Direct Flow prosthesis via the
transfemoral route.
WHAT IS NEXT? The data have to be conﬁrmed by a larger
study with longer follow-up.
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1849second-generation repositionable and recapturable
devices, the DFM valve has a unique anchoring
mechanism with 2 inﬂatable ring balloons, which
does not need the presence of calcium and may have
a better sealing.
STUDY LIMITATIONS. The limitations of this study
are those inherent to the retrospective design and the
lack of an echocardiography and angiography core
laboratory or an independent event adjudication
committee. The small sample size and short follow-up
time also limit any conclusions about long-term
safety or stability of the valve in patients. However,
this study does provide data on feasibility, technique,
and sizing of the DFM that may facilitate the treat-
ment of a larger group of high-risk or inoperable pa-
tients with pure AR.
CONCLUSIONS
This study reports the feasibility of treating pure
native AR with the Direct Flow valve, which can be
implanted transfemorally and has the advantages of afully retrievable and repositionable valve. The acute
results obtained here need to be conﬁrmed in a larger
study.
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